Citius Oncology (NASDAQ:CTOR) officially transitioned from a development-stage clinical trial outfit to a revenue-generating commercial entity this quarter, posting its first sales of the newly approved immunotherapy LYMPHIR.
The Cranford, New Jersey-based biotech reported $3.9 million in revenue for its fiscal first quarter ended Dec. 31, 2025.
The sales were generated in the final month of the year following the U.S. commercial launch of LYMPHIR (denileukin diftitox-cxdl), an IL-2 receptor-directed therapy for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
The drug, which received FDA approval in August 2024, targets a rare form of non-Hodgkin lymphoma that has seen few new systemic treatment options in nearly a decade.
The quarter was defined by the rapid stand-up of a nationwide specialty distribution network.
To fuel the commercial engine, Citius Oncology fortified its balance sheet with a registered offering in December, raising $15.1 million in net proceeds.
The company ended the quarter with $7.3 million in cash on hand, providing a baseline for its near-term marketing and distribution expenses.
Financial results for the quarter included a net loss of $5.5 million, or $0.06 per share.
Research and development expenses were pared down to $1 million as the focus shifted to the market, while general and administrative costs—which include the bulk of the commercial infrastructure build-out—totaled $2.9 million.
Beyond the U.S., Citius is laying the groundwork for global expansion.
The company recently announced exclusive distribution agreements to bring LYMPHIR to the European Union, Turkey, and the Middle East through managed access programs.
These international partnerships aim to capture value from a global CTCL market that management estimates currently exceeds $400 million.